Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation
- 6 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 112 (1), 96-104
- https://doi.org/10.1007/s12185-020-02874-1
Abstract
We report a case of acquired dysfibrinogenemia with monoclonal gammopathy of undetermined significance presenting λ-type IgA M protein. The patient showed lower functional (0.4 g/dL) and normal immunological fibrinogen (2.9 g/dL). To examine the cause of the false lower value of fibrinogen, we performed experiments using the patient’s purified fibrinogen and IgA. Fibrinogen was purified from the patient’s plasma; IgA was purified from plasma or serum by immunoaffinity chromatography. We performed thrombin-catalyzed fibrin polymerization, scanning electron microscopy (SEM), immunoblotting analysis, and enzyme-linked immunosorbent assays (ELISAs). Fibrin polymerization in the patient’s plasma was markedly reduced and SEM showed no fiber bundles or sponge-like structures. Purified IgA did not influence polymerization, whereas immunoprecipitated plasma with an anti-IgA (α-chain) antibody indicated normalization of polymerization and clot structure. Western blotting analysis revealed the presence of monoclonal λ-type IgA-bound fibrinogen, the proportion of which was significantly higher than normal control plasma using ELISA. Our results suggest that IgA M protein-bound fibrinogen is not normally converted into fibrin, but rather leads to formation of an aberrantly structured fragile clot. The patient’s reduced plasma fibrinogen level was caused by the presence of IgA M protein-bound fibrinogen, not by IgA M protein alone.Keywords
Funding Information
- Japan Society for the Promotion of Science (17K09009)
This publication has 26 references indexed in Scilit:
- Congenital Fibrinogen Disorders: An UpdateSeminars in Thrombosis and Hemostasis, 2013
- Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BβGly15Cys (Hamamatsu II)Blood Coagulation & Fibrinolysis, 2009
- Acquired Dysfibrinogenemia Secondary to Multiple MyelomaActa Haematologica, 2008
- Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin light chainHaematologica, 2007
- Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin.Journal of Clinical Pathology, 1994
- Inhibition of Fibrin Monomer Polymerization by Bence Jones Protein in a Patient with Primary AmyloidosisActa Haematologica, 1989
- Dysfibrinogenemia in Obstructive Liver DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1987
- Case Report: Acquired Dysfibrinogenemia Secondary to Mithramycin ToxicityThe American Journal of the Medical Sciences, 1986
- THE ABNORMAL CARBOHYDRATE COMPOSITION OF THE DYSFIBRINOGENEMIA ASSOCIATED WITH LIVER DISEASE*Annals of the New York Academy of Sciences, 1983
- Acquired dysfibrinogenaemia in liver disease.Journal of Clinical Pathology, 1982